Hims & Hers Health (HIMS) Surges 27.7%: Is This an Indication of Further Gains?
Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Hims & Hers Terrifies Big Pharma
Hims & Hers (HIMS 1.82%) launched a Super Bowl ad this week, and everyone from pharmaceutical companies to pharmacists tried to block it. Travis Hoium explains why that's a great sign that the company's disruptive potential is real.
Hims & Hers Health: Explosive Growth Potential Ahead
Hims & Hers has shown significant growth, with a 350% stock gain in 2024, driven by subscriber and revenue increases, and positive free cash flow. The company boasts a strong balance sheet with $250M in cash, no debt, and strategic share repurchases, enhancing shareholder value. Future growth is expected from personalized solutions, with the potential to expand the subscriber base by millions and grow revenue per subscriber.
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The decliners were Novo Nordisk (NVO -2.90%), famously the company behind Wegovy, and Viking Therapeutics (VKTX -7.34%), which is far along in its development of an advanced GLP-1-based obesity treatment.
Hims & Hers Super Bowl ad sparks controversy over weight loss drug sourcing
CNBC's Brandon Gomez breaks down the controversy around the Hims & Hers Super Bowl ad.
Hims & Hers Super Bowl ad draws scrutiny from lawmakers
Hims & Hers Health (HIMS) stock moves a notch higher Monday morning after the company's weight-loss drug ad played during the Super Bowl. The commercial's airing raised concerns from health experts and US lawmakers over the exclusion of potential side effects tied to GLP-1 weight-loss treatments in the advertisement.
Hims & Hers Super Bowl ad sparks controversy
CNBC's Brandon Gomez joins 'Squawk on the Street' to break down the controversy around Hims & Hers Super Bowl ads.
Hims & Hers Health: Meme Potential Could Propel Explosive Growth
Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Putting aside Hims meme potential, the company is still in a great position to disrupt the healthcare industry given its unique platform and business model. While Hims is building an increasingly innovative and high-quality business model, the company still faces major regulatory and competitive hurdles.
Hims & Hers stock price target according to the C&H pattern
Hims & Hers stock price continues to fire on all cylinders this year and is hovering near its highest level on record. It has soared by almost 1,500% from its lowest level in 2023, transforming it into a leading juggernaut with a market cap of over $9.3 billion.
Hims & Hers faces backlash over ‘misleading' Super Bowl ad—but it didn't stop stock from jumping over 11%
Telehealth company Hims & Hers Health is fighting back after the drug industry's main lobbying group called out its first Super Bowl ad as “misleading” and in potential violation of marketing rules.
Hims & Hers faces scrutiny from lawmakers over 'misleading' Super Bowl ad
Hims & Hers is under fire over an ad for its weight loss offerings that's slated to run during the Super Bowl on Sunday. Two U.S. senators expressed concern over an "upcoming advertisement" that "risks misleading patients by omitting any safety or side effect information.
Why Hims & Hers Health (HIMS), Tempus AI (TEM) and Teladoc (TDOC) Are Up Big Today
Stock markets got a bit of a shock on Friday after a University of Michigan survey showed consumers are anticipating inflation to rise in 2025, potentially depressing consumer spending and dissuading the Fed from making any further cuts to interest rates.
